Advertisement

BMC Gastroenterology

, 19:204 | Cite as

Irritable bowel syndrome-like symptoms and health related quality of life two years after Roux-en-Y gastric bypass - a prospective cohort study

  • Ingvild Kristine Blom-HøgestølEmail author
  • Martin Aasbrenn
  • Monica Chahal-Kummen
  • Cathrine Brunborg
  • Inger Eribe
  • Jon Kristinsson
  • Per G. Farup
  • Tom Mala
Open Access
Research article
Part of the following topical collections:
  1. Epidemiology of gastroenterological disorders

Abstract

Background

Irritable bowel syndrome (IBS) is prevalent in patients with morbid obesity. After Roux-en-Y gastric bypass (RYGB) chronic abdominal pain is common, however the etiology is largely unknown. We aimed to study the change in the prevalence of IBS-like symptoms 2 years after RYGB and possible preoperative predictors of such symptoms. Secondly, to evaluate changes in symptoms of constipation and diarrhea, and Health related quality of life (HRQoL).

Methods

Patients with morbid obesity were included at two obesity centers in South-Eastern Norway. IBS was diagnosed according to the Rome III criteria. Predictors were evaluated in a multivariable logistic regression analysis.

Results

Of 307 participants operated with RYGB, 233 (76%) completed the study questionnaires. Preoperatively 27/233 participants (12%) had IBS, 2 years after RYGB 61/233 (26%) had IBS-like symptoms (p < 0.001). Eleven participants with IBS preoperatively (41%) did not report such symptoms after RYGB. New onset IBS-like symptoms was identified in 45/206 (22%) after RYGB. Fibromyalgia, low LDL levels, high vitamin B1 levels and IBS before RYGB were independent preoperative predictors of IBS-like symptoms at the follow-up visit. Symptom scores for constipation preoperatively and 2 year after RYGB were 1.5 (0.9) and 1.8 (1.2), and for diarrhea 1.4 (0.9) and 1.8 (1.1), respectively (p < 0.001). We observed a significant improvement in the physical component score for all participants. However, participants with new onset IBS-like symptoms had a significant worsening of the mental component score.

Conclusions

The prevalence of IBS-like symptoms doubled 2 years after RYGB, and these symptoms were associated with reduced HRQoL. Preoperative IBS and fibromyalgia were strong predictors of postoperative IBS-like symptoms.

Keywords

Irritable bowel syndrome Morbid obesity Roux-en-Y gastric bypass Gastrointestinal symptoms Fibromyalgia Health related quality of life 

Abbreviations

BMI

Body mass index

CRP

C-reactive protein

GSRS

Gastrointestinal Symptoms Rating Scale

HbA1c

Glycosylated hemoglobin

HDL

High-density lipoprotein

HRQoL

Health related quality of life

IBS

Irritable bowel syndrome

IHT-G

Innlandet Hospital Trust Gjøvik

LDL

Low-density lipoprotein (LDL)

OUH

Oslo University Hospital

RYGB

Roux-en-Y gastric bypass

SF-36

36-Item Short Form Health Survey (SF-36)

T2D

Type 2 diabetes

TSH

Thyroid stimulating hormone

Background

Irritable bowel syndrome (IBS) affects around 10% of adult populations [1]. IBS might be even more common in patients with morbid obesity [2, 3]. The core symptom of IBS is frequent abdominal pain associated with changes in bowel habits. The underlying pathophysiology is multifactorial and includes a combination of psychological factors and gut related factors (as changes in motility, inflammation or the gut microbiome) [4]. The diagnosis IBS is based on symptom-based criteria [5].

Roux-en-Y gastric bypass (RYGB) is the second most common surgical procedure applied in the treatment of morbid obesity when conservative measures have failed [6]. RYGB enables a large and sustained weight loss, improvement of obesity-related co-morbidities and health related quality of life (HRQoL), with low risk of surgical complications [7, 8, 9]. However, recent reports indicate that abdominal pain is common 2–5 years after RYGB [10, 11, 12]. Internal herniation and gallstone related disease are common causes of acute pain, whereas the etiology of chronic abdominal pain after RYGB is less well understood [13, 14, 15].

The primary aims of this study were to study the change in the prevalence of IBS-like symptoms from before to 2 years after RYGB and to search for preoperative predictors of these symptoms after RYGB. Furthermore we aimed to study changes in scores of constipation, diarrhea and HRQoL in all participants and in those with and without IBS-like symptoms.

Methods

Study design and setting

This is a prospective cohort study, where we invited patients with morbid obesity at the obesity centers at Oslo University Hospital (OUH) and Innlandet Hospital Trust Gjøvik (IHT-G), Norway, to participate. Participants who underwent RYGB were invited for a follow-up consultation 2 years after RYGB. Participants at OUH and IHT-G were recruited during February 2014 to June 2015, and December 2012 to September 2014, respectively. Follow-up was completed June 2017 and May 2017 at OUS and IHT-G, respectively. Subject with morbid obesity who previously has failed non-surgical measures of weigh loss were considered eligible for. Morbid obesity was defined as having a body mass index (BMI) ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with obesity-related comorbidity. Exclusion criteria for study inclusion were age younger than 18 or older than 60 years, previous bariatric surgery, other indications for RYGB than morbid obesity, simultaneous cholecystectomy, other serious disorders unrelated to obesity (including organic gastrointestinal disorder) and inability to read Norwegian language.

Surgical procedure and study visits

All RYGB operations were performed in a standardized manner, with a laparoscopic approach, a gastric pouch of about 25 ml, a 150 cm antecolic alimentary and a 50 cm biliopancreatic limb [16]. Mesenteric defects were routinely closed with non-absorbable staplers. Study visits were performed preoperatively and 2 years after RYGB. At study visits, demographics, medical history, and were registered in a predefined case report form. A routine clinical examination was performed including anthropometric measurements, and fasting blood samples were retrieved. If symptoms or clinical examination was susceptive of organic gastrointestinal disorder additional diagnostic evaluations including endoscopic examinations were made according to the clinician’s discretion. All patients filled in questionnaires for the classification of IBS, gastrointestinal symptoms and HRQoL.

Outcomes

Five demographic variables were evaluated: Age (years), gender (male/female), BMI (kg/m2), employment status (full time/not working) and cohabitant status (living with partner/not living with partner). Five co-morbid conditions were evaluated: Type 2 diabetes (T2D), hypothyroidism, hypertension, fibromyalgia, and minor psychiatric disorders (anxiety or depression). The information concerning co-morbidity was given by the participant and reviewed by a clinician with full access to the patient’s medical record. T2D was defined as HbA1c ≥ 6.5%, or the use of one or more oral glucose lowering drugs, with or without insulin treatment. Diabetes remission was defined as HbA1c < 6.5% without use of glucose lowering drugs, in a participant with prior T2D.

IBS, IBS-like symptoms, gastrointestinal symptoms and HRQoL

IBS and IBS-like symptoms were evaluated by the Rome III questionnaire in a validated translation to Norwegian [5]. Preoperatively participants who fulfilled the Rome III criteria for IBS were classified as having IBS, postoperatively participants who fulfilled the Rome III criteria for IBS were classified as having IBS-like symptoms. Our study protocol did not include supplementary examinations of participants fulfilling the Rome III criteria to explore underlying pathophysiology of IBS or IBS-like symptoms. Rome III evaluates pain and discomfort without differentiating these measures. Furthermore, participants reporting preoperative IBS did not receive any treatment addressing IBS symptoms as part of this study or to our knowledge by others. Thus the presented IBS population likely represents an untreated IBS population. Notably, no restrictions were placed on participants in regard to seeking medical attention for IBS related symptoms.

Symptoms of constipation and diarrhea were evaluated using the Gastrointestinal Symptoms Rating Scale (GSRS). The patients responded using a Likert-type scale (1 = no discomfort and 7 = severe discomfort) [17]. The GSRS-IBS questionnaire was used at IHT-G, and the GSRS at OUS. Common variables from the two questionnaires were used to calculate the constipation and diarrhea symptom scores reported in this article.

Participants from OUS reported HRQoL at the preoperative and 2 year follow-up visit, participants from IHT-G reported HRQoL only at the 2 year follow-up visit. To evaluate HRQoL the Norwegian validated translation of the 36-Item Short Form Health Survey (SF-36) version 2 was used [18]. The SF-36 questionnaires were scored using the QualityMetric Health Outcomes™ Scoring Software 4.5 giving eight health domains; physical functioning, physical role functioning, bodily pain, general health perception, vitality, social role functioning, emotional role functioning and mental health, and two summary scores; physical component score and mental component score.

Blood tests

The reference values for the fifteen variables reported in the results are as follows: hemoglobin g/dL: women 11.7–15.3, men 13.4–17.0; iron μmol/L: 9–34; ferritin μg/L: women 10–170, men 30–400; white-cell count 109/L: 3.5–10.0; c-reactive protein (CRP) mg/L: < 5; cholesterol mmol/L: age 18–29 2.9–6.1, age 30–49 3.3–6.9, age > 50 3.9–7.8; high-density lipoprotein (HDL) mmol/L: women 1.0–2.7, men 0.8–2.1; low-density lipoprotein (LDL) mmol/L: age 18–29 1.3–4.3, age 30–49 1.5–4.8, age > 50 2.0–5.4; triglycerides mmol/L: 0.5–2.6; thyroid stimulating hormone (TSH) mIE/L: 0.5–3.6; vitamin B1 nmol/liter: 95–200; vitamin B6 nmol/liter: 15–160; vitamin B12 pmol/L: 150–650; folic acid nmol/L: 7–40; glycosylated hemoglobin (HbA1c) %: 4.0–6.0.

Statistical analysis

Paired-sample t–tests or Wilcoxon rank test were used for evaluation of changes in continuous variables between preoperative and 2 year follow-up. McNemar’s test for paired proportions was used for evaluation of changes in categorical variables. For comparing subgroups independent sample t-test was used. Missing data for the GSRS item scores was imputed using the mean score of the non-missing items. Patient characteristics associated with IBS-like symptoms were studied by using independent sample t-test, the Chi Square test or Fisher exact test as appropriate.

Logistic regression analysis was performed to identify preoperative predictors of IBS-like symptoms 2 years after RYGB. Any variable associated with p < 0.25 from the univariable analysis were entered into a multivariable logistic regression model using a manual backward stepwise elimination procedure. Centre of inclusion and IBS at baseline were forced into the multivariable model. Multivariable analyses were preceded by estimation of correlation between risk factors. Predictors that correlated > 0.7, were not included in the model in order to avoid multicollinearity. The association between preoperative characteristics and IBS-like symptoms at the 2 year follow-up visit was quantified by odds ratio (OR) with 95% confidence intervals (CI). Two tailed p-values < 0.05 were considered statistically significant. All statistical analyses were made using the IBM SPSS statistics version 25.0 (IBM SPSS Inc., Armonk, NY: IBM Corp). The results are given as mean with standard deviation (SD) in brackets if not otherwise indicated.

Results

Of 307 participants operated with RYGB, 240 (78%) attended the 2 year follow-up visit and 233 (76%) filled out the study questionnaires (Fig. 1). In total 45 (19%) of 233 included participants were operated at IHT-G. Table 1 gives the participants’ characteristics at the preoperative and the 2 year follow-up visits.
Fig. 1

Flow chart describing the inclusion of participants

Table 1

Patient characteristics at the preoperative visit and the 2 year follow-up visit after Roux-en-Y-gastric bypass

 

Preoperative visit

n = 233

Two year follow-up visit

n = 233

Statistics

(p-values)

Gender (male/female)

56 (24%)/177 (76%)

  

Age (years)

43.5 (9.1)

  

Body mass index (kg/m2)

42.9 (4.9)

29.5 (4.6)

<0.001

Living with partner

161 (71%)

172 (76%)

0.03

Full time work

130 (58%)

127 (56%)

0.78

Type 2 diabetes

55 (24%)

18 (8%)

<0.001

Hypertension

98 (43%)

34 (15%)

<0.001

Hypothyroidism

22 (10%)

24 (10%)

0.73

Fibromyalgia

33 (14%)

36 (16%)

0.61

Self-reported psychiatric disorder

40 (17%)

37 (16%)

0.76

Irritable bowel syndrome

27 (12%)

61 (26%)

<0.001

IBS-constipation

5 (2%)

11 (5%)

0.15

IBS-diarrhea

5 (2%)

12 (5%)

0.09

IBS-mixed

16 (7%)

34 (15%)

0.004

IBS-unsubtyped

1 (0.4%)

3 (1%)

0.63

Hemoglobin (g/dl)

14.2 (1.1)

13.7 (1.1)

<0.001

Iron (mol/L)

15.1 (5.2)

19.6 (6.9)

<0.001

Ferritin

104.5 (8–584)

115.0 (4–804)

0.31

White-cell count (×109/liter)

7.7 (2.1)

6.2 (1.9)

<0.001

HbA1c (%)

5.7 (4.6–14.9)

5.2 (4.0–9.7)

<0.001

C-reactive protein (mg/liter)

7.0 (0–50.0)

0.6 (0–66.0)

<0.001

Cholesterol (mmol/liter)

4.9 (1.0)

4.3 (0.7)

<0.001

High-density lipoprotein (mmol/liter)

1.2 (0.3)

1.7 (0.4)

<0.001

Low-density lipoprotein (mmol/liter)

3.2 (0.9)

2.5 (0.7)

<0.001

Triglycerides

1.9 (1.3)

1.0 (0.5)

<0.001

Vitamin B1 (nmol/liter)

157.4 (27.8)

159.6 (27.7)

0.18

Vitamin B6 (nmol/liter)

36.5 (34.9)

52.8 (44.0)

<0.001

Vitamin B12 (pmol/liter)

375.8 (166.8)

531.4 (321.3)

<0.001

Folic acid (nmol/liter)

20.3 (9.0)

22.2 (10.6)

0.014

The results are given as number (proportion in per cent) for categorical variables, mean (SD) for continuous variables with normal distribution and median (min-max) for other variables. Significant p-values are marked in bold

Data were analyzed with McNemar test for categorical variables and paired t-tests or Wilcoxon signed-rank test (marked with†) for continuous variables

For one patient, we had insufficient information for subtyping of IBS at the 2 year follow-up visit

Missing variables: Living with partner (n = 7), Full time work (n = 7), type 2 diabetes (n = 3), Hypertension (n = 4) Hypothyroidism (n = 4), Fibromyalgia (n = 4), minor psychiatric disorder (n = 4), Hemoglobin (=2), Iron (n = 2), Ferritin (n = 7), White-cell count (n = 3), HbA1c (n = 2), CRP (n = 3), Cholesterol (n = 2), High-density lipoprotein (n = 2), Low-density lipoprotein (n = 2), Triglycerides (n = 2), Vitamin B1 (n = 4), Vitamin B6 (n = 4), Vitamin B12 (n = 2), Folic acid (n = 2)

*Two de-novo diabetes mellitus

Prior to the RYGB surgery 27 participants (12%) had IBS, 2 years after surgery 61 (26%) reported IBS-like symptoms (p < 0.001). 11/27 (41%) of those with IBS before RYGB did not report IBS-like symptoms after RYGB. New onset IBS-like symptoms were identified in 45/206 (22%) of participants without IBS preoperatively (Fig. 2), representing 19% of the total population at the 2 year follow-up visit.
Fig. 2

Prevalence of Irritable bowel syndrome (IBS) at the preoperative visit and IBS-like symptoms at the 2 year follow-up visit after Roux-en-Y-gastric bypass. IBS status was defined according to the Rome III criteria. The prevalence of symptoms of IBS increased from 12 to 26% (p < 0.001)

Fibromyalgia, low LDL levels, high vitamin B1 levels and IBS before RYGB were independent preoperative predictors of IBS-like symptoms at the 2 year follow-up visit (Table 2). Among participants without IBS at the preoperative visit, fibromyalgia and high vitamin B1 levels were independent preoperative predictors of IBS-like symptoms at follow-up (data not shown).
Table 2

Preoperative predictors of irritable bowel syndrome (IBS)-like symptoms 2 years after Roux-en-Y-gastric bypass (RYGB)

Preoperative characteristics

Patients without IBS-like symptoms after RYGB

n = 172

Patients with IBS-like symptoms

after RYGB

n = 61

Odds ratio

(95% CI)

Statistics

(p-values)

Adjusted for all significant predictors and center of inclusion

 

Odds ratio

(95% CI)

Statistics

(p-values)

Gender (female)

127/172 (74%)

50/61 (82%)

1.6 (0.77–3.4)

0.20

  

Age (years)

43.3 (9.3)

43.3 (8.4)

1.0 (0.94–1.0)

0.66

  

Body mass index (kg/m2)

42.8 (4.9)

43.1 (4.6)

1.0 (0.96–1.1)

0.65

  

Living with partner

118/171 (69%)

47/61 (77%)

1.5 (0.77–3.0)

0.24

  

Working full time

105/171 (61%)

28/61 (46%)

0.53 (0.30–0.96)

0.037

  

Smokers

39/168 (23%)

10/59 (17%)

0.68 (0.31–1.5)

0.32

  

Type 2 diabetes

42/172 (24%)

15/61 (25%)

1.0 (0.51–2.0)

0.98

  

Hypertension

74/171 (43%)

25/61 (40%)

0.76 (0.50–1.7)

0.76

  

Hypothyroidism

14/172 (8%)

8/61 (13%)

1.7 (0.68–4.3)

0.26

  

Fibromyalgia

16/171 (9%)

17/61 (28%)

3.7 (1.8–8.0)

0.001

4.1 (1.7–9.8)

0.001

Self-reported psychiatric disorder

26/172 (15%)

14/61 (23%)

1.7 (0.81–3.5)

0.17

  

IBS before RYGB

11/172 (6%)

16/61 (26%)

5.2 (2.6–12.0)

< 0.001

7.2 (2.8–18.6)

< 0.001

Hemoglobin (g/dl)

14.1 (1.1)

14.3 (1.1)

1.1 (0.86–1.5)

0.41

  

Iron (μmol/L)

15.0 (5.3)

15.6 (5.1)

1.0 (0.97–1.1)

0.43

  

Ferritin (μg/L)

144 (130.3)

138 (103.8)

1.0 (0.99–1.0)

0.74

  

White-cell count (×109/liter)

7.6 (2.1)

7.7 (2.1)

1.0 (0.88–1.8)

0.83

  

HbA1C (%)

6.1 (1.4)

6.0 (1.4)

0.94 (0.75–1.8)

0.58

  

Thyroid stimulating hormone (x10E-3 IU/L)

1.7 (0.95)

2.2 (1.9)

1.3 (1.0–1.7)

0.039

  

C-reactive protein (mg/liter)

7.7 (6.3)

7.7 (5.5)

1.0 (0.95–1.1)

0.99

  

Cholesterol (mmol/liter)

5.0 (1.0)

4.8 (0.95)

0.82 (0.61–1.1)

0.20*

  

High-density lipoprotein (mmol/liter)

1.2 (0.31)

1.2 (0.25)

0.86 (0.32–2.4)

0.77

  

Low-density lipoprotein (mmol/liter)

3.2 (0.92)

3.0 (0.75)

0.81 (0.58–1.1)

0.20

0.66 (0.45–0.96)

0.031

Triglycerides (mmol/L)

1.86 (1.4)

1.88 (1.2)

1.0 (0.81–1.3)

0.93

  

Vitamin B1 (nmol/liter)

155 (28.1)

162 (27.2)

1.0 (0.99–1.0)

0.11

1.0 (1.0–1.0)

0.013

Vitamin B6 (nmol/liter)

36.6 (36.9)

36.0 (27.9)

1.0 (0.99–1.0)

0.91

  

Vitamin B12 (pmol/liter)

384 (182)

350 (110)

1.0 (1.0–1.0)

0.17

  

Folic acid (nmol/liter)

20.0 (9.0)

20.9 (8.8)

1.0 (0.98–1.0)

0.50

  

The results are given as number (proportion in per cent) for categorical variables, and mean (SD) for continuous variables with normal distribution. Preoperative characteristics associated with IBS-like symptoms 2 years after RYGB were studied with univariate regression. Any variable associated from the univariate analysis (with p < 0.25) were entered into a multivariable logistic regression model using a manual backward stepwise elimination procedure. In total, 10 potential predictors were examined in the multivariable analysis (p-values written in bold). Cholesterol was not included in the final analysis due to high correlation with LDL

Symptom scores for constipation at the preoperative and 2 year follow-up visits were 1.5 (0.9) and 1.8 (1.2) (p < 0.001), and for diarrhea 1.4 (0.9) and 1.8 (1.1) (p < 0.001), respectively. Table 3 shows the changes in constipation and diarrhea scores in all participants, and stratified by IBS status. The most pronounced worsening of constipation and diarrhea symptom scores was found in the groups without IBS before RYGB and the group with new onset IBS-like symptoms after RYGB.
Table 3

Changes in constipation and diarrhea symptom scores from preoperatively to 2 years after Roux-en-Y Gastric bypass (RYGB)

Group

n

Δ constipation symptom score

95% CI

p-value

n

Δ diarrhea symptom score

95% CI

p-value

All participants

174

−0.29

−0.44 to −0.14

<0.001

177

−0.40

−0.58 to −0.22

<0.001

Subgroups based on IBS status preoperatively:

 With IBS

21

−0.19

−0.66 to 0.28

0.41

21

−0.38

−1.1 to 0.34

0.28

 Without IBS

153

−0.31

−0.46 to −0.15

<0.001

156

−0.40

−0.58 to −0.22

<0.001

Subgroups based on IBS like symptoms 2 years after RYGB:

 Never IBS or IBS-like symptoms

116

−0.16

−0.32 to 0.012

0.068

119

−0.31

−0.50 to − 0.11

0.002

 New onset IBS-like symptoms

37

−0.77

−1.13 to − 0.42

<0.001

37

− 0.71

− 1.15 to − 0.27

0.002

 IBS preoperatively and IBS-like symptoms at 2 year follow-up visit

14

− 0.24

− 0.75 to 0.28

0.34

14

− 0.24

− 1.3 to 0.78

0.62

All participants, and subgroups based on status of irritable bowel syndrome (IBS) are presented. Significant p-values are marked in bold

The presented delta values: Gastrointestinal Symptom Rating Scale (GSRS) at the 2 year follow-up visit - GSRS at the preoperative visit. Positive delta values indicate improved symptoms after RYGB, negative delta values indicate worsened symptoms after RYGB. The results are given as mean values with 95% confidence intervals (CI). Data were analyzed with paired t-tests

New onset IBS: no IBS preoperatively, but IBS-like symptoms 2 years after RYGB. Never IBS: No IBS preoperatively or IBS-like symptoms 2 years after RYGB

Missing data Δ constipation symptom score: All participants; n = 59. Subgroups based on IBS status preoperatively: with IBS; n = 6, without IBS; n = 53. Subgroups based on IBS-like symptoms 2 years after RYGB: never IBS or IBS-like symptoms; n = 45, new onset IBS-like symptoms; n = 8, IBS at preoperative and IBS-like symptoms 2 year follow-up visit; n = 2

Missing data Δ diarrhea symptom score: All participants; n = 56. Subgroups based on IBS status preoperatively: with IBS; n = 6, without IBS; n = 50, never IBS; n = 42. Subgroups based on IBS-like symptoms 2 years after RYGB: new onset IBS-like symptoms; n = 8, IBS at preoperative and IBS-like symptoms 2 year follow-up visit; n = 2

Prior to RYGB, HRQoL was comparable between participants with and without IBS. At the 2 year follow-up visit participants with IBS-like symptoms had significantly lower HRQoL scores in all eight health domains and both summary scores compared to participants without IBS-like symptoms (Fig. 3). In participants with and without IBS at the preoperative visit, the improvements in the mean physical component score were 0.54 (12.8) and 7.6 (10.6) (p = 0.047) respectively and mental component scores decreased with 1.2 (10.7) and 2.6 (8.2) (p 0.67) respectively. Table 4 shows the changes in physical component score and mental component score in all participants and subgroups.
Fig. 3

Health related quality of life in participants with and without irritable bowel syndrome (IBS) and IBS-like symptoms, before and 2 years after Roux-en-Y gastric bypass (RYGB)

Table 4

Changes in Physical Component Scores (PCS) and Mental Component Scores (MCS) from preoperatively to two year after Roux-en-Y Gastric bypass (RYGB)

Group (number of participants)

n

Δ PCS

95% CI

p-value

Δ MCS

95% CI

p-value

All participants

153

7.1

5.4 to 8.8

<0.001

−1,25

−2.9 to 0.44

0.15

Subgroups based on IBS at preoperative visit:

 With IBS

10

0.54

−8.6 to 9.7

0.90

−2.6

−8.5 to 3.2

0.33

 Without IBS

143

7.6

5.8 to 9.3

<0.001

−1.2

−2.9 to 0.62

0.20

Subgroups based on IBS-like symptoms 2 years after RYGB:

 Never IBS or IBS-like symptoms

113

7.68

5.8 to 9.6

<0.001

0.29

−1.5 to 2.1

0.75

 New onset IBS-like symptoms

30

7.15

2.8 to 11.5

0.002

−6.59

−11.3 to − 1.9

0.007

 IBS at preoperative and IBS-like symptoms 2 year follow-up visit

6

−3.3

−14.1 to 7.5

0.47

−4.9

−14.8 to 5.0

0.26

All participants, and subgroups based on status of irritable bowel syndrome (IBS) are presented. Significant p-values are marked in bold

The SF-36 questionnaires were scored using the QualityMetric Health Outcomes™ Scoring Software 4.5 giving the presented Physical Component Scores (PCS) and Mental Component Scores (MCS)

The presented delta values: SF-36 value at the 2 year follow-up visit - SF-36 value at the preoperative visit. Positive delta values indicate improved score after RYGB and negative values indicate worsened score after RYGB. The results are given as mean values with 95% confidence intervals (CI). Data were analyzed with paired t-tests

New onset IBS-like symptoms: no IBS before RYGB, but IBS-like symptoms 2 years after RYGB. Never IBS or IBS-like symptoms: No IBS before or IBS-like symptoms 2 years after RYGB

Missing data: All participants; n = 80. Subgroups based on IBS at preoperative visit: with IBS; n = 17, without IBS; n = 63. Subgroups based on IBS-like symptoms 2 years after RYGB: never IBS or IBS-like symptoms; n = 48, new onset IBS-like symptoms; n = 15, IBS at preoperative and IBS-like symptoms 2 year follow-up visit; n = 10

Discussion

The prevalence of IBS-like symptoms more than doubled 2 years after RYGB. IBS-like symptoms thus appears to be a relevant contributing factor for chronic abdominal pain and symptoms after RYGB. It has been hypothesized that low-grade inflammation could be an important cause of IBS in patients with morbid obesity [19]. In our study, the prevalence of IBS-like symptoms increased in a period where obesity-related inflammation decreased for the majority of participants, weakening this hypothesis.

Participants with preoperative fibromyalgia had four times higher odds of IBS-like symptoms after RYGB than participants without fibromyalgia. Fibromyalgia and IBS may share similar pain processing dysfunctions, such as reduced pain inhibition and aberrant autonomic nervous system responses [20, 21, 22]. The considerable weight reduction and the associated reduction of various obesity related symptoms after RYGB may impact the weighting of different bodily sensations (Table 1), and thus in combination with altered gastrointestinal physiology may affect the prevalence of perceived IBS-like symptoms.

Unexpectedly, high levels of vitamin B1 before RYGB was an independent preoperative predictor of IBS-like symptoms 2 year post surgery. This finding may be a proxy indicating a specific diet used by these patients or it may be a statistical type 1 bias. The finding should be further explored in future studies.

Participants with lower LDL at the preoperative visit had higher probability of IBS-like symptoms at the 2 year follow-up visit. Previous reports note an association between higher LDL and IBS both in subjects with and without obesity [23, 24]. RYGB induces structural changes in gastrointestinal tract, affects the regulation of several gut hormones including those involved in hunger and satiety, and has been shown to affect the responses of the cerebral frontoparietal control network involved in food preference regulation and non-food cues [25, 26, 27]. The net effect is decreased intake of food, enhanced satiety responses and a shift in food preferences from high-energy to low-energy. The pathophysiology of IBS before RYGB could thus differ from that of IBS-like symptoms post RYGB. In subjects with morbid obesity, before surgery, IBS may be more related to the diet or the lipid metabolism [24], while after RYGB IBS-like symptoms could be more related to disturbances in pain perception and altered gastrointestinal physiology.

Both constipation and diarrhea symptoms increased after RYGB, with a comparable mean change in participants with and without IBS at the preoperative visit. Previous studies have shown diverging dynamics of these symptoms after RYGB [12, 28, 29]. However, although statistically significant, the absolute changes in mean diarrhea and constipation symptom score are unlikely to be of high clinically importance (< 15% increase in symptom score), with exception of the subgroup of participants with new onset of IBS-like symptoms after RYGB who experienced a mean 33% increase for both diarrhea and constipation symptom scores.

The observed improvements in the physical functioning aspects of HRQoL after RYGB have previously been described [9, 12]. However, we are the first to describe that the improved physical functioning is irrespective of the presence of IBS-like symptoms after RYGB. Participants with and without IBS at the preoperative visit had comparable HRQoL. This was surprising, but may be due to the limited number of participants with IBS and HRQoL data available before surgery. After RYGB participants with IBS-like symptoms had significantly lower HRQoL than participants without such symptoms, in line with previous reports [30].

Of the 206 participants without IBS preoperatively 45 (22%) had new onset IBS-like symptoms 2 years after surgery. This group had a larger increase in diarrhea and constipation symptom scores and a decrease in the mental component score of SF-36 after RYGB. These findings supports an association between IBS-like symptoms after RYGB and worsened psychosocial functioning, and highlight the impact IBS-like symptoms may have on patients’ lives after RYGB [31]. The high rate of IBS-like symptoms after surgery and the reduced HRQoL associated with such symptoms should be part of the preoperative information to patients eligible for bariatric surgery and a clinical focus during follow-up, including guidance in how to reduce symptoms.

Participants with IBS before surgery had seven times higher odds for IBS-like symptoms 2 years after RYGB than those without IBS prior to surgery. However, in participants with IBS preoperatively we observed unchanged HRQoL after RYGB. And it is worth to point out that of the 27 participants with IBS preoperatively 11 (41%) no longer had IBS-like symptoms 2 years after RYGB. Therefore, IBS prior to RYGB should not be considered as an absolute contraindication for surgery.

The large numbered cohort, the high rate of follow up, and the prospective design are important strengths of our study compared to earlier reports. The use of a validated translation of the Rome III and the SF-36 questionnaires and the comprehensive evaluation of all participants are other strengths.

This study contains several major limitations. The study did not differentiate between the different functional abdominal pain syndromes. Participants fulfilling the Rome III criteria for IBS were not systematically examined for underlying pathophysiology of IBS-like symptoms. To what extent the altered physiology or other aspects of the surgical procedure itself contributed to the increase in bowel symptoms could not be answered by this study. In particular, evaluation of small intestinal bacterial overgrowth would be relevant in the evaluation of symptoms. Reporting on the use of medication at follow-up may have added information relevant for interpretation of our findings, particularly medications affecting gastrointestinal function. A control group consisting of patients undergoing other abdominal surgery could add information relevant to the interpretation of our findings.

The large number of variables imposes a risk of type 1 statistical errors. Correction for multiple testing was not performed, but all analyzed variables are presented transparently. Only participants from OUS were evaluated with SF-36 preoperatively. Gastrointestinal symptoms were evaluated with two subtypes of GSRS, thus limiting the study to only report diarrhea and constipation symptom scores for which questions in the two questionnaires were identical. A more precise diagnosis of psychiatric disorders could have strengthened the study.

Blood tests were analyzed at two local laboratories. However for paired sample tests a difference between the laboratories would not affect the results, as all patients were seen at the same center at the preoperative and the 2 year follow-up visits.

Conclusions

The prevalence of IBS-like symptoms more than doubled and was associated with reduced HRQoL after RYGB. Preoperative IBS and fibromyalgia were strong predictors of such symptoms 2 years after RYGB, yet most of the patients with IBS-like symptoms after surgery had new onset of symptoms.

Notes

Acknowledgments

We deeply appreciate the support from Marianne Sæter and Irene Ruud Johannessen at the Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, for their assistance in patient recruitment and questionnaire retrieval. We thank MD, PhD Kristin Engebretsen for the help with patient follow-up.

Authors’ contributions

Study design: IKBH, MA, CB, JAK, PGF and TM. Study conduct: IKBH, MA, MCK, IE, PGF, JAK and TM. Data collection: IKBH, IE, MCK and MA. Data analysis: IKBH, MA, CB and PGF. Data interpretation: IKBH, MA, CB, JAK, PGF and TM. IKBH and CB take responsibility for the integrity of the data analysis. Drafting manuscript: IKBH, MA, PGF and TM. Revising manuscript content: IKBH, MA, MCK, CB, IE, JAK, PGF and TM. Read and approve of the final version of manuscript: IKBH, MA, MCK, CB, IE, JAK, PGF and TM.

Funding

The first author (IKBH) has received a PhD grant from South-Eastern Norway Regional Health authority, project nr 2014073. The project has received a financial grant from the Norwegian Gastroenterology Association, but had no role in the design of the study, data collection, analysis and interpretation of data or in writing the manuscript.

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki and approved by the Regional Committee for Medical and Health Research Ethics South East Norway; 2013/1264 and 2012/966. Written informed consent was obtained from all participants.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66(6):1075–1082. PubMed PMID: 26818616. Epub 2016/01/29. eng.CrossRefGoogle Scholar
  2. 2.
    Fysekidis M, Bouchoucha M, Bihan H, Reach G, Benamouzig R, Catheline JM. Prevalence and co-occurrence of upper and lower functional gastrointestinal symptoms in patients eligible for bariatric surgery. Obes Surg 2012;22(3):403–410. PubMed PMID: 21503810. Epub 2011/04/20. eng.CrossRefGoogle Scholar
  3. 3.
    Bouchoucha M, Fysekidis M, Julia C, Airinei G, Catheline JM, Reach G, et al. Functional gastrointestinal disorders in obese patients. The importance of the enrollment source. Obes Surg 2015;25(11):2143–2152. PubMed PMID: 25904236. Epub 2015/04/24. eng.CrossRefGoogle Scholar
  4. 4.
    Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med 2017;376(26):2566–2578. PubMed PMID: 28657875. Epub 2017/06/29. eng.CrossRefGoogle Scholar
  5. 5.
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491. PubMed PMID: 16678561. Epub 2006/05/09. eng.CrossRefGoogle Scholar
  6. 6.
    Angrisani L, Santonicola A, Iovino P, Vitiello A, Zundel N, Buchwald H, et al. Bariatric surgery and Endoluminal procedures: IFSO worldwide survey 2014. Obes Surg 2017;27(9):2279–2289. PubMed PMID: 28405878. Pubmed Central PMCID: PMC5562777. Epub 2017/04/14. eng.CrossRefGoogle Scholar
  7. 7.
    Courcoulas AP, King WC, Belle SH, Berk P, Flum DR, Garcia L, et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study. JAMA surgery 2018;153(5):427–434. PubMed PMID: 29214306. Epub 2017/12/08. eng.CrossRefGoogle Scholar
  8. 8.
    Suter M, Donadini A, Romy S, Demartines N, Giusti V. Laparoscopic roux-en-Y gastric bypass: significant long-term weight loss, improvement of obesity-related comorbidities and quality of life. Ann Surg 2011;254(2):267–273. PubMed PMID: 21772127. Epub 2011/07/21. eng.CrossRefGoogle Scholar
  9. 9.
    Risstad H, Sovik TT, Hewitt S, Kristinsson JA, Fagerland MW, Bernklev T, et al. Changes in health-related quality of life after gastric bypass in patients with and without obesity-related disease. Obes Surg 2015;25(12):2408–2416. PubMed PMID: 26003550. Epub 2015/05/25. eng.CrossRefGoogle Scholar
  10. 10.
    Hogestol IK, Chahal-Kummen M, Eribe I, Brunborg C, Stubhaug A, Hewitt S, et al. Chronic abdominal pain and symptoms 5 years after gastric bypass for morbid obesity. Obes Surg 2017;27(6):1438–1445. PubMed PMID: 28028658. Epub 2016/12/29. eng.CrossRefGoogle Scholar
  11. 11.
    Gribsholt SB, Pedersen AM, Svensson E, Thomsen RW, Richelsen B. Prevalence of self-reported symptoms after gastric bypass surgery for obesity. JAMA surgery 2016;151(6):504–511. PubMed PMID: 26747510. Epub 2016/01/10. eng.CrossRefGoogle Scholar
  12. 12.
    Chahal-Kummen MIB-H, Eribe I, Klungsøyr O, Kristinsson J, Mala T. Abdominal pain and symptoms before and two years after roux-en-Y gastric bypass. BJS Open. 2019;3:317–26.CrossRefGoogle Scholar
  13. 13.
    Pernar LI, Lockridge R, McCormack C, Chen J, Shikora SA, Spector D, et al. An effort to develop an algorithm to target abdominal CT scans for patients after gastric bypass. Obes Surg 2016;26(10):2543–2546. PubMed PMID: 27523471. Epub 2016/08/16. eng.CrossRefGoogle Scholar
  14. 14.
    Blom-Hogestol IK, Stubhaug A, Kristinsson JA, Mala T. Diagnosis and treatment of chronic abdominal pain 5 years after roux-en-Y gastric bypass. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 2018;14(10):1544–1551. PubMed PMID: 30449511. Epub 2018/11/20. eng.CrossRefGoogle Scholar
  15. 15.
    Pierik AS, Coblijn UK, de Raaff CAL, van Veen RN, van Tets WF, van Wagensveld BA. Unexplained abdominal pain in morbidly obese patients after bariatric surgery. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 2017;13(10):1743–1751. PubMed PMID: 28728833. Epub 2017/07/22. eng.CrossRefGoogle Scholar
  16. 16.
    Schauer PR, Ikramuddin S, Hamad G, Eid GM, Mattar S, Cottam D, et al. Laparoscopic gastric bypass surgery: current technique. Journal of laparoendoscopic & advanced surgical techniques Part A 2003;13(4):229–239. PubMed PMID: 14561251. Epub 2003/10/17. eng.Google Scholar
  17. 17.
    Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33(2):129–134. PubMed PMID: 3123181. Epub 1988/02/01. eng.Google Scholar
  18. 18.
    Karlsen TI, Tveita EK, Natvig GK, Tonstad S, Hjelmesaeth J. Validity of the SF-36 in patients with morbid obesity. Obes Facts 2011;4(5):346–351. PubMed PMID: 22166753. Epub 2011/12/15. eng.CrossRefGoogle Scholar
  19. 19.
    Pickett-Blakely O. Obesity and irritable bowel syndrome: a comprehensive review. Gastroenterol Hepatol 2014;10(7):411–416. PubMed PMID: 25904828. Pubmed Central PMCID: PMC4302488. Epub 2015/04/24. eng.Google Scholar
  20. 20.
    Kurland JE, Coyle WJ, Winkler A, Zable E. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Dig Dis Sci 2006;51(3):454–460. PubMed PMID: 16614951. Epub 2006/04/15. eng.CrossRefGoogle Scholar
  21. 21.
    Veale D, Kavanagh G, Fielding JF, Fitzgerald O. Primary fibromyalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process. Br J Rheumatol 1991;30(3):220–222. PubMed PMID: 2049586. Epub 1991/06/01. eng.CrossRefGoogle Scholar
  22. 22.
    Chalaye P, Goffaux P, Bourgault P, Lafrenaye S, Devroede G, Watier A, et al. Comparing pain modulation and autonomic responses in fibromyalgia and irritable bowel syndrome patients. Clin J Pain 2012;28(6):519–526. PubMed PMID: 22673485. Epub 2012/06/08. eng.CrossRefGoogle Scholar
  23. 23.
    Gulcan E, Taser F, Toker A, Korkmaz U, Alcelik A. Increased frequency of prediabetes in patients with irritable bowel syndrome. Am J Med Sci 2009;338(2):116–119. PubMed PMID: 19561452. Epub 2009/06/30. eng.CrossRefGoogle Scholar
  24. 24.
    Aasbrenn M, Hogestol I, Eribe I, Kristinsson J, Lydersen S, Mala T, et al. Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: a cross-sectional study. BMC obesity 2017;4:22. PubMed PMID: 28680646. Pubmed Central PMCID: PMC5490229. Epub 2017/07/07. eng.Google Scholar
  25. 25.
    Goldstone AP, Miras AD, Scholtz S, Jackson S, Neff KJ, Penicaud L, et al. Link between increased satiety gut hormones and reduced food reward after gastric bypass surgery for obesity. J Clin Endocrinol Metab 2016;101(2):599–609. PubMed PMID: 26580235. Pubmed Central PMCID: PMC4880130. Epub 2015/11/19. eng.CrossRefGoogle Scholar
  26. 26.
    Zoon HFA, de Bruijn SEM, Smeets PAM, de Graaf C, Janssen IMC, Schijns W, et al. Altered neural responsivity to food cues in relation to food preferences, but not appetite-related hormone concentrations after RYGB-surgery. Behav Brain Res 2018;353:194–202. PubMed PMID: 30041007. Epub 2018/07/25. eng.CrossRefGoogle Scholar
  27. 27.
    Kvehaugen AS, Farup PG. Changes in gastrointestinal symptoms and food tolerance 6 months following weight loss surgery: associations with dietary changes, weight loss and the surgical procedure. BMC obesity 2018;5:29. PubMed PMID: 30524734. Pubmed Central PMCID: PMC6276242. Epub 2018/12/14. eng.Google Scholar
  28. 28.
    Sovik TT, Karlsson J, Aasheim ET, Fagerland MW, Bjorkman S, Engstrom M, et al. Gastrointestinal function and eating behavior after gastric bypass and duodenal switch. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2013;9(5):641–647. PubMed PMID: 22951078. Epub 2012/09/07. eng.CrossRefGoogle Scholar
  29. 29.
    Clements RH, Gonzalez QH, Foster A, Richards WO, McDowell J, Bondora A, et al. Gastrointestinal symptoms are more intense in morbidly obese patients and are improved with laparoscopic roux-en-Y gastric bypass. Obes Surg 2003;13(4):610–614. PubMed PMID: 12935364. Epub 2003/08/26. eng.CrossRefGoogle Scholar
  30. 30.
    Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. Journal of managed care pharmacy: JMCP 2013;19(9):755–764. PubMed PMID: 24156644. Epub 2013/10/26. eng.CrossRefGoogle Scholar
  31. 31.
    Przekop P, Haviland MG, Zhao Y, Oda K, Morton KR, Fraser GE. Self-reported physical health, mental health, and comorbid diseases among women with irritable bowel syndrome, fibromyalgia, or both compared with healthy control respondents. The Journal of the American Osteopathic Association 2012;112(11):726–735. PubMed PMID: 23139343. Pubmed Central PMCID: PMC3542981. Epub 2012/11/10. eng.Google Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of EndocrinologyMorbid Obesity and Preventive Medicine, Oslo University HospitalOsloNorway
  2. 2.Institute of Clinical MedicineUniversity of OsloOsloNorway
  3. 3.Department of Geriatrics and Internal MedicineBispebjerg and Frederiksberg HospitalCopenhagenDenmark
  4. 4.Department of SurgeryInnlandet Hospital TrustGjøvikNorway
  5. 5.Oslo Centre for Biostatistics and Epidemiology, Research Support ServicesOslo University HospitalOsloNorway
  6. 6.Department of Gastrointestinal Surgery and Paediatric SurgeryOslo University HospitalOsloNorway
  7. 7.Unit for Applied Clinical Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health SciencesNorwegian University of Science and TechnologyTrondheimNorway
  8. 8.Department of ResearchInnlandet Hospital TrustBrumunddalNorway

Personalised recommendations